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Introduction
Clinical researches of new medicaments and medical
products on animals and humans  are preceding and un-
avoidable stage before its application. While from the legal
standpoint animals are objects and, therefore, can be con-
sidered as things within a clinical research, a human be-
comes legal subject in all areas of his actions by the mo-
ment of birth, including clinical research performed over it.
Although underlining this fact might be considered super-
fluous, World War II and Nazi camps should not be for-
gotten 
1 for the cruelest medical experiments performed
against humans without their consent, treating them as
mere objects. Modern history also gives examples of hu-
mans' abuse for these purposes 
2, due to which commenced
legal stipulation of the position of people participating in
clinical research, as well as terms under which this is pos-
sible. Although general agreement exists that clinical trials
cannot be denied regardless the risks they carry against
health of its subjects – there is also a general agreement
that we have to renounce trials performed disrespecting
subjectivity of those who are subjects of it 
3.
To respect subjectivity of persons who are the subjects
of clinical research means their consent to submit themselves
to research 
4. We can, thus, name consent the border line
between a human as a subject and an object of the research.
Realizing its importance, experts from the area of medicine,
ethics and law defined terms for consent to be fulfilled in or-
der to consider it valid 
5. Therefore, many international and
national regulations set rules for that. However, those regu-
lations are often not harmonized, and the same issue is
stipulated in different manners and no clear guidelines are
given to researchers how to act, although they are often per-
sonally tasked to get subjects' consent. Researchers also do
not have all the rules in one document which if to be applied
guarantees getting valid subjects’ consent and protection of
their subjectivity, but also protection from potential re-
searcher's accountability for getting invalid consent.
Having all the mentioned in mind, we collected and
analyzed terms that have to be fulfilled in order to consider
validity of subject’s consent for medical research, starting
from solutions in the Serbian law, as well as in international
legal and ethics-related documents. In that spirit, we stress as
the most important that consent originates from legally com-
petent person or legally authorized representative of legally
incompetent person or person incapable of giving consent; it
has to be given voluntarily, i.e. must not have shortcomings
in a form of the so-called “defects of will”; and must have
the attribute of an informed one. A precise definition of
terms for validity of research subject's consent in Serbia,
however, is not an easy task both for a lawyer and for a phy-
sician, since regulations regarding this are given in several
legal texts: the Health Care Act 
6, the Medicines and Medical
Devices Act 
7, the Family Act 
8, the Obligations Act 
9, as
well as in Guidelines for Good Practice in Clinical Research
(Guidelines) 
10, and in international conventions ratified by
Serbia. The number of these regulations that have to be kept
in mind, can be a problem for a researcher, therefore, objec-
tive of our paper was to facilitate researchers in their focus
on medical aspects by analysis of legal aspects of consent to
clinical researches. Finally, in the last part of the paper, we
will indicate also the form of possible accountability of re-
searchers for performing clinical trials with no valid subjects'
consent.
Legal competence of the subject
Minimal quality of each consent marking it as “abso-
lutely essential”, the term for any experiment against hu-
mans, ever since the Nuremberg Code 
11 till today, is to be
voluntary. Since consent to participate in clinical research in
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voluntary only if it originates from a person that can formu-
late legally relevant will, i.e. legally competent person. Legal
competency of a person by the rule means its reasoning ca-
pability 
12–14. Legally competent (research) subject can be
temporarily incapable of reasoning (under influence of alco-
hol, drugs, etc.), but that is obvious for a researcher and
therefore consent getting in such shape can be avoided.
However, in some states reasoning capability in this context
is considered more relevant than legal competency 
15; thus, it
is taken that each person capable of reasoning can give valid
consent. Although this position is not illogical, we think that
a subject in Serbia has to be legally competent in order to
give valid consent (all until corresponding regulations do not
foresee differently), and that a researcher has to take care
also of the existence of subjects’ capability to reason and to
inform a competent authority if it recognizes that this lacks
temporarily or permanently for some reason.
1. Legal competency is gained by the majority that in
different states means different ages – most often 18 (also
relevant for Serbia), 21 or 25, with the tendency to lower this
limit. Exclusively, legal competency can be acquired even
earlier by the so-called public emancipation, if that is ac-
knowledged to a certain person by the decision of competent
authority (unlike private emancipation, given by parents, that
is not possible in Serbia). Reasons to acknowledge legal
competency before the majority are different, and in Serbia
that is possible for persons married by the permission of the
court or who became parents independently of being married
even if in the age of 16 but mature, capable to independently
take care of him(her)self and personal rights and interests
(Article 11 and 23 of the Family Act). These persons keep
their legal competency even if the marriage is terminated.
For a researcher it is relevant to obtain legally relevant
statement of will from every legally competent person, and
therefore also valid consent – independently of how and
when the subject gained that legal competency.
Legally incompetent minor, therefore, cannot give duly
valid consent to participate in clinical researches, but most of
international and national regulations provide an option for
that – to be done by their legal representatives instead (or be-
side them). Serbian Medicines and Medical Devices Act
(Article 63) went, however, one step further, prescribing the
ban of participation in clinical researches for this category of
persons. Exclusively, they can be research subjects with the
consent of their legally authorized representatives only if suf-
fering of illness or are in the stages of illness for which clini-
cally tested medicine is intended to (if that is necessary and
under special precautions measures); or they are healthy and
their participation in the medical experiment is for their in-
terest. Thus, no difference is made between therapeutic and
non-therapeutic experiments, as it is done in some European
countries 
16.
This Serbian regulation, however, does not deal with
legally competent or legally incompetent persons, but intro-
duces this ban for persons under 18. Since some minors, as
mentioned, can gain legal competency even before the ma-
jority, the question is raised are they capable of giving duly
valid consent? We could solve this dilemma starting with the
question: is getting age of 18 in life legally or medically
relevant? The answer is simple: turning 18 is legally relevant
because it leads to legal ages and legal competency. From
the medical viewpoint, this fact is not relevant, since it hap-
pens that exact participation of these persons in research is
needed. It is also the fact that different states link legal com-
petency to different ages; and from this viewpoint it is clear
that a Serbian legislator obviously had in mind legal compe-
tency – not ages as such – when prescribing ban of partici-
pation in research for persons under 18. The law linked ban
to ages most probably because the number of situations when
minors are also legally competent is negligible small. There-
fore, it was more correct to use the term “legal competency”
in this law instead of indicating ages, as done in for ex. the
Health Protection Act (Article 38) regulating validity of the
consent to medical measure. We consider that persons under
18 in Serbia can also give duly valid consent to clinical re-
searches if they are legally competent (legal competence
means also capability of reasoning, since it is granted by the
court. In any case, in order to remove any possible perplexi-
ties, the Medicines and Medical Devices Act could also fore-
see, as by the model of Serbian Organs Transplantation
Act 
17, that person giving its consent to participate in clinical
trails – exactly as person giving consent to donate its or-
gans 
18 has to be both legally competent and capable of rea-
soning, as well of legal age (Article 42 etc.). Although, by
the general rule, mentioned characteristics of one person
exit's simultaneously (an adult is both legally competent and
capable of reasoning) such regulation would solve dilemmas
in explicit situations where that is not the case.
The question that is raised in relation to legally author-
ized representative in this context is: should we make a dif-
ference there between persons under 14 and those between
14 and 18 (junior and senior minors), as by general rules of
Serbian law contained in the Family Act or not? According
to these rules, the difference between these categories of per-
sons are that senior minors are limited in their legal compe-
tency and they can independently give duly valid statements
of will, and thus also consents to researches – if obtain pre-
vious or latter consent of the legally authorized representa-
tive. Junior minors cannot independently give statements of
will (except for jobs of smaller significance or jobs not cre-
ating particular obligations for them), but representatives
give consent on their behalf (Articles 64, 72, etc. of the
Family Act) – something researcher has to take care of. It is
an opinion of ours that these general rules should be valid
also in the context of consents to participate clinical re-
searches, because consent is a statement of will as any other.
2. Researchers have to have in mind that not all adults
are legally competent. Some of them – incapable of reason-
ing or to take care of themselves and protection of their
rights and interests, or they directly endanger their or others
interests (ill persons, person with difficulties in psycho-
physical development, etc. - Articles 146–147 of the Family
Act), can be denied of legal competency totally or partly by
the decision of competent authority. These persons also can-
not give duly valid consent to clinical research; therefore, a
researcher has to inquire do they also have legal competency,Strana 590 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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except of being over 18, as requested by the legislator. It
would be good to foresee this by regulations, i.e. have this
question as a mandatory content of the interview between re-
searcher and potential subject. This is also an argument sup-
porting the position that existence of legal competency is
important both for persons over 18 – not only ages. Even if
subjects are adults lacking legal competency, their consent
given in the so-called lucida intervalla of a mental illness,
cannot be considered duly valid for legal certainty reasons –
until legal competency is acknowledged back by the decision
of a competent authority.
According to the majority of international and national
regulations, as well as according to the Serbian Medicines
and Medical Devices Act (Article 61) both legally incompe-
tent and adults with limited legal competency can be in-
volved in the research, if consent is given by their legally
authorized representatives (also including some other terms
fulfilled, but not elaborated here since those are not the topic
of our paper). By this Act, however, a consent of a legal rep-
resentative is necessary also for legally competent adults in-
capable of giving the consent (ex. state of unconsciousness)
– under the condition they did not reject to give consent to
participate the study before their incompetence begun (Arti-
cle 66). Mentioned expansion of the group of adults for who
consent is given by legal representatives is acceptable, be-
cause those persons at the given moment are obviously inca-
pable to give valid consent although formally legal compe-
tence exists; however, the question is raised: Who are their
legally authorized representatives 
19? Since the mentioned
Act does not define this, ɚ representative of the legally com-
petent person in such state cannot be nominated by the re-
searcher – the only solution left is that this should be done by
the guardianship body. But, it can perform such action just
after it denies legal competency of such person by the proce-
dure prescribed by the Family Act, and this requires time. On
the other hand, the question is will then the consent of
(newly) appointed guardian be of any relevance, particularly
if subject incompetence was of temporary character and
clinical research referred exactly to the state in which subject
person was (ex. state of unconsciousness). Therefore, we
consider that this Act should foresee options of analogue en-
forcement of regulations from the Health Care Act (Article
34) by which such consent to a medical measure can be sub-
stituted by the conclusion of a consilium; however, this op-
tion, to our opinion, should be limited only to experiments
having therapeutic character.
3. As the following question we should consider: on the
basis of which criteria can legally authorized representatives
give consent on behalf of the subject they represent 
20, 21? Do
they give consent starting from their personal position; i.e.
would they give it if they were in the position of the repre-
sented person; or they should give it independently of their
beliefs (religious and others), but taking care exclusively of
interests of the represented person 
22? The second approach
is obviously more correct, but what guarantees we may have
that representative will act that way? Therefore, it is our
opinion that each legally authorized representative or at least
guardian as legal representative should obtain consent of the
guardianship body, before it gives consent to participation of
the represented person in a medical experiment, particularly
if it is of nontherapeutic character. In the Family Act of Ser-
bia there already is a provision (Article 137) by which a
guardian can give consent to a medical treatment over a pro-
tégé only with the consent of guardianship authority; and the
Health Care Act (Article 35) foresees the obligations of a
health worker to inform a guardian authority if he/she consid-
ers that consent of a legal representative (both guardian and
parents) to a medical measure is not in the best interest of the
represented patient. Since medical experiments are not of the
same relevance for the subject, as medical treatment for the
purpose of curing, even more important would be to oblige the
legally authorized representative to obtain consent of the
guardianship authority before giving any further consent.
Hence, the fact is that neither international regulations
nor the Medicines and Medical Devices Act. of Serbia which
in details regulates clinical research, foresee this – we con-
sider this an omission to be corrected. The literature contains
the position by which request to engage guardianship
authority needs to be rejected, since it can lead to prolonga-
tions of the research commence. Our opinion, however, is
that if one subject decides of the submission of other subject
to testing which are not medically necessary with certain
risks against the subject (which always exist) – then the re-
search commence has to wait and an opportunity has to be
given to the guardianship authority to examine the whole
situation. To the objection that a guardianship authority is
medically incompetent and that ethical committees are suffi-
cient, we have to respond that analogue to that legally
authorized representatives are incompetent in this sense, too,
as well as subjects, but again asked for their consent. Finally,
ethical committees assess permissibility of  the clinical re-
search wider, from the aspect of numerous ethical and medi-
cal principles; therefore, those cannot sufficiently focus on
issues if a legally authorized representative gives a consent
justifiably or unjustifiably on behalf of the represented per-
son. Their starting point is a consent as already given and
they consider it in other context – was it given on the basis of
correctly composed questionnaire, were the subject person
and his representative sufficiently informed, etc. (Articles 64
and 73 of the Medicines and Medical Devices Act). On the
other hand, guardianship authority has different assessment
methods and criteria, other composition and experience in
work, as well findings on the relation between the repre-
sented person and the representative; therefore, their previ-
ous assessment in this domain is considered important, be-
sides the assessment done by ethical committees in a certain
latter stage. Finally, if participation in researches can, by the
opinion of experts, positively reflect upon the health of le-
gally incompetent subject or it is in his/her interest for other
reasons, it should not be suspected that position of his
guardianship authority will be positive. The position of the
guardianship authority will not be as such only if participa-
tion in researches is really problematic from the aspect of
represented person and its representative for some reasons
intends to give its consent, particularly when the represented
person is opposing to that.Volumen 71, Broj 6 VOJNOSANITETSKI PREGLED Strana 591
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The following question imposes this: can a legally
authorized representative give consent for participation of a
represented person in a clinical research if such person is op-
posing to it, even after the assessment that it is in his inter-
est? Reasons for this can be plain ones – ex. fear of a child
from “people in white”, etc. The Medicines and Medical De-
vices Act gives an answer to this question: consent is accept-
able only if it is an expression of assumed will of legally in-
competent persons (Article 64 and 66). Therefore, argu-
mentum  a contrario, their discontent cannot lead to duly
valid consent of the legal representative. Regulations of cer-
tain states 
23, as well some international regulations 
24, 25, ex-
plicitly foresee that besides the consent of a legal representa-
tive, consent of a minor is also necessary; and that the rejec-
tion of participation in researches by such subject has to be
respected. Exception is allowed if out of research no therapy
exists for minor’s illness, or minor’s therapeutic benefit is in
prospect. If elder children are opposing to research, the re-
searcher needs to obtain a license for continuation of an ex-
periment from scientific or ethical committees. Finally, by
the Serbian Family Act (Article 62) and the Health Care Act
(Article 35), a minor who turned 15 (and capable of reason-
ing) can individually give consent to a medical measure, and
other legally incompetent persons should be involved in the
process of decision making related to its undertaking – there-
fore, there is no reason not to take into consideration the
opinion of those persons also in relation to participation in
clinical researches.
Voluntary consent
Ban to subject someone to a clinical research or ex-
periment without its free-will consent is foreseen by interna-
tional 
26–28, as well as national legal acts (commonly, by con-
stitutions) and means respect of individual's autonomy 
29 and
right of every human being to self-determination 
30. The
Constitution of Serbia 
31 guarantees that “no one can be …..
subjected to medical or scientific experiments without his
consent given by free will” (Article 25). This means that ex-
pression of will, representing the consent of the subject, must
not have any shortcomings, i.e. there has to be harmony be-
tween internal and expressed will of the subject. Causes of
the disharmony can be numerous.
1. Consent of the subject or his legal representative
can be a consequence of fraud, threat or coercion by a re-
searcher or a third person, and therefore it is neither free
will nor valid. That originates both from the Guideline,
forbidding coercion or other inappropriate impact on the
subject (point 4.8.3.); also, from the analogue enforcement
of the Serbian Obligations Act referring to expression of
will in contracts (Ariticle 60–65, 112 and 117). Such ex-
pression of will can be made void, since it is not in har-
mony with the real expression of subject's will, while per-
son obtaining consent in this way shall also be responsible
for that. Hence, it is important to stress that this is right,
but not also an obligation of the subject, and therefore its
implementation is not obligatory (Article 112 of the Obli-
gations Act).
2. Threat against the subject, however, may not always
be an explicit one. It happens that some subjects who are in a
dependent relationship with the researcher give their consent
under the impact of fear from negative consequences of re-
jection – although not directly threatened by the researcher.
Those, for example, can be medicine students or clinical staff
to whom the researcher is a superior, as well as persons
whose physician he/she is. In order to prevent this situation,
it would be good to exclude the researcher from the process
of all or at least such subjects' recruitment; and, this task
should be given to an appropriately qualified individual in-
dependent on this relationship. Since this is not an easily fea-
sible requirement in countries having low research resources,
the other option is to eliminate the mentioned subjects from
the list of possible subjects. The Serbian Medicines and
Medical Devices Act (Article 63) selected the second option,
foreseeing that persons whose free-will consent to participate
in clinical research can be influenced by coercion or some
other way of impact – cannot be participants of those. The
Guideline (point 1.61.) classify this category of subjects as
vulnerable subjects, i.e. those for who it is presumed that
have diminished ability to protect one's interests manifested
by a compromised capability to give voluntary consent to
participation in an experiment 
32. Beside them, it is possible
also that consent of other categories of vulnerable subjects is
not essentially free will due to fear of negative consequences
of rejection, and that should be taken care of 
33.
3. The right to annul consent belongs also to the subject
giving it in deception, where he got under no influence of
others, personal or others guilt. Although convinced that he
understood well all in relation to forthcoming research, it
may happen that the subject got incorrect idea of the real
situation and as such gave the consent which for this is not
duly valid. This and the next quality of the consent are
closely related, since one of the aims of subject's informing
before the consent is to be given is exactly to remove any
possible deceptions.
4. Finally, consent has to be given seriously, not in a
joke, and this is guaranteed also by the requirement to have it
formally, i.e. in written, signed and dated, i.e. given before a
witness if the subject is not able to read (points 4.8.8. and
4.8.9. of the Guideline and Article 61 of the Medicines and
Medical Devices Act).
Informing the subject before giving the consent
The next term of consent fulfillment validity which is
required by all international and national regulations, is that a
subject has to be informed about what he/she actually ac-
cepts prior to the clinical trial participation. This consent is
in short named “informed consent”. Some regulations, such
are international conventions dealing with the problem of
human rights, stay at the stage of proclamation – not entering
into the details when it is actually considered that this term is
fulfilled [Convention on Human Rights and Biomedicine
(Article 16); Universal Declaration on Bioethics and Human
Rights UNESCO (Article 6), etc.]. International and national
regulations of clinical research involving human subjects,Strana 592 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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however, elaborate this issue in details. On the basis of the
analysis, we conclude that a subject can be considered in-
formed if two conditions are cumulatively fulfilled: one of
objective and the other one of subjective character. Objective
condition is fulfilled if the subject is provided with all infor-
mation necessary to overview the situation where he will get
into and by this make a decision of consent. Subjective con-
dition means that the obtained information is well-
understood by the subject.
Objective condition
It is very obvious in international regulations related to
clinical research involving human subjects that different
manners that regulate what the subject has to be informed
about and in what scope in order to consider his/her consent
informed. Some of those determine the scope and the object
of informing in an abstract manner, while others concretely
list types of information the researcher has to present to the
subject 
34.
By the Nuremberg Code, the subject can give a consent
which is considered informed if he/she sufficiently knows of
“the nature, duration and purpose of the experiment, the
method and means by which it is to be conducted; all incon-
veniences and hazards reasonable to be expected; and the ef-
fects upon his/her health or person which may possibly come
from his/her participation in the experiment” and if he/she
understood provided information.
The Declaration of Helsinki stresses the need for sub-
ject's adequate informing, necessity of provided information
understanding and provided full freedom when consent is
being given (Article 24). The object of informing is set a bit
wider in this Declaration than in the Nuremberg Code and
can purport duty to inform the subject about: “aims, meth-
ods, sources of funding, any possible conflicts of interest, in-
stitutional affiliations of the researcher, the anticipated bene-
fits and potential risks of the study and the discomfort it may
entail, and any other relevant aspects of the study”.
The Directive 20/2001 of the European Parliament and
the Council from 2001 
35 underlines that the requirement for
informed consent is fulfilled if the subject was duly informed
on the “nature, significance, implications and risks of the
study” [Article 2, par. 1, point (ʁ)].
According to the International Ethical Guidelines for
Biomedical Research Involving Human Subjects, informed
consent exists if it was given by the competent subject who
adequately understood necessary information which was
provided (Guideline 4). This document differs from the pre-
viously mentioned because it in details regulates what is nec-
essary information that a researcher has to present to a po-
tential subject, giving list of 26 points.
The guidelines for Good Clinical Practice 
36 do not de-
fine subject's informing as a short-term act, but as “a process
by which a subject voluntarily confirms his or her willing-
ness to participate in a particular trial, after having been in-
formed of all aspects of the trial that are relevant to the sub-
ject's decision to participate.” As the previously mentioned
document, the Guidelines also do not just abstractly deter-
mine the scope and the content of the right to be informed
(point 4.8.10.). Those elaborate the subject of informing also
through indication of a wide list of 20 information to be pre-
sented to the subject.
On the basis of the presented we could, above all, con-
clude that there is a disharmony in respect of terminology
used in international regulations to determine scope and ob-
ject of the obligation to inform the subject, as well as that
quite a few regulations define this obligation more con-
cretely. The obligation to inform is mostly defined abstractly
and requires more precise definition; this is obviously left to
a person obtaining the consent. At the end, this can lead to
selective and by subjective criteria chosen scope and object
of subject's informing. The space left for assessment in each
individual case with how much information the level of
“adequate”, “necessary” or “sufficient” was reached can en-
danger reaching the quality for the informed one and by this
duly valid subject's consent reflecting negatively in respect
of his rights. On the other side, such regulations neither do
sufficiently protect interest of researchers who can be treated
as responsible for infringement of the obligation to inform
the subject.
Under the Serbian law, the scope and object of subject's
informing were determined within the Health Care Act – if it
is about medical experiments (Article 38), and the Medicines
and Medical Devices Act – if it is about clinical trials of
medicines (Article 2). The first mentioned foresees that a pa-
tient over who a medical experiment is performed has to be
“sufficiently informed about the sense, goal, procedures, ex-
pected results, possible risks, as well as inconvenient accom-
panying circumstances of the experiment”; the other men-
tioned defines informed consent as written statement of the
subject “which is given voluntarily after duly informing on
the nature, significance, consequences and risk to health”.
The Medicines and Medical Devices Act in its Article 59 re-
fers also to implementation of already analyzed Guidelines.
The mentioned indicates that the Health Care Act determines
the scope of an obligation to inform the subject slightly nar-
rower than the Medicines and Medical Devices Act (suffi-
ciently informed is less than duly informed), while the scope
of information which are object of informing are determined
slightly wider.
Having in mind recognized differences, the question is
raised: which legal text the researcher should follow per-
forming the duty to inform the subject, as clinical trails are a
certain form of medical experiments? Since in the area of
clinical researches the Health Care Act has a character of
general one (lex generalis), and the Medicines and Medical
Devices Act of special one (lex specialis), the obligation of
informing for the purpose of clinical research should be har-
monized with the second mentioned which refers to imple-
mentation of the Guideline; therefore, a researcher in Serbia
has the obligation of duly informing of the subject about all
concrete information foreseen in the Guideline. In this way,
respect of autonomy of potential participant in clinical re-
search is fully ensured, as well as credibility of the re-
searcher; therefore, we could conclude that the scope and
object of the obligation to inform the subject is adequately
and widely set in the Serbian law.Volumen 71, Broj 6 VOJNOSANITETSKI PREGLED Strana 593
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Subjective condition
Fulfillment of just analyzed, objective condition of the
informed consent, i.e. providing necessary information to a
subject – is not enough, if the subject did not understand it.
Therefore, most of the referred regulations particularly un-
derline the necessity to fulfill subjective condition, too.
Some researches with this topic show, however, that in
practice exactly fulfillment of this condition lacks 
37–39, and
providing consent to access the study is made equal to ful-
fillment of its objective, but the formal side of its validity –
by communication of necessary information with signing of
proper form. Obtaining essentially informed consent, how-
ever, has to have features of a process comprised of the
procedure of information repetition, its additional clarifica-
tion, responding to questions, etc. – all to the end of cogni-
tion that those are clear to the subject (point 4.8.7. of the
Guideline). Important way to achieve this goal is to use
words and expressions understandable both for the medi-
cally “illiterate” subject (point 4.8.6. of the Guideline).
Some studies 
40 showed that use of certain methods in order
to improve understanding of provided information, like
multimedia presentations or extension of the form intended
to inform the subject, did not give the expected results. On
the other hand, extended discussion on the relation re-
searcher-subject proved as the most efficient way to im-
prove understanding, as well as the use test method, i.e.
asking for a feedback in order to check was the provided
information understood well. Therefore, with the aim to
reach legally and ethically acceptable and essentially duly
valid consent to include people in clinical research, we
suggest implementation of these methods in the procedure
of potential subject selection in Serbia.
Responsibility for conducting clinical researches
with invalid consent
If the researcher approaches clinical research with no
consent of the subject or with his/her consent not fulfilling
the mentioned conditions to be considered duly valid – the
issue of researcher’s responsibility will be raised, and it can
be civil, criminal or both 
41.
a) Civil responsibility means obligation of the re-
searcher to compensate material and non-material damage
suffered by the subject for being subjected to the clinical re-
search without any or duly valid consent, and it is a fault of
the researcher. It is an infringement of personality right. The
researcher can't insure him(her)self against the responsibility
for this kind of damage, for reasonable causes. Mandatory
insurance of the subject refers to possible damages he/she
could suffer as a consequence of participation in research
performed by law (Article 72 of the Medicines and Medical
Devices Act and Article 38 of the Health Care Act), but not
from the damage suffered due to its involvement in the re-
search with invalid consent.
b) The second form of researchers' responsibility in this
situation is a criminal one, that will be raised if his/her action
has features of a criminal act under the name “Illegal Conduct
of Medical Experiments and Testing of Medicaments”, fore-
seen in many countries by the Penal Code, as in Serbia (Article
252) 
42, in the group of criminal offences against human
health. A person shall be responsible for it, if: 1) against regu-
lations performs medical and other similar experiment or clini-
cal testing of drugs against people; and 2) clones people or
performs experiments with that objective. While ban to clon-
ing has an absolute character, medical and other similar re-
search involving human subjects or clinical researches of
drugs can be performed and responsibility of the researcher
shall be raised only if done against regulations. The Guideline
(point 4.1.3.) explicitly foresee that researcher has to know and
respect regulations applicable in this field. Since the funda-
mental condition foreseen by Serbian and international regula-
tions for medical experiments is the subject consent (which
has to have all the features mentioned in this paper to be con-
sidered duly valid) – for this criminal offence shall be respon-
sible the researcher who commits this intentionally without
such consent. By the law, criminal offence is committed by the
final performance of the described action (a research with no
duly valid consent, in our case), and it is not necessary to es-
tablish did any other consequence appeared 
43.
Beside the mentioned criminal offence, a person who
provided the consent of a subject (or his legally authorized
representative) to do something, not to do something or suf-
fer in clinical research, by use of coercion, force or threat,
shall also be responsible for the criminal offence of coercion
(Article 135 of the Penal Code).
Conclusion
On the basis of everything presented in the paper we
would like to make several conclusions.
Firstly, it is of tremendous importance for researchers to
precisely know which terms have to be fulfilled in order to
consider consent to clinical researches duly valid: both for
possible serious consequences to the autonomy and subjec-
tivity of the subject and its right to self-determination in re-
gard to its body, as well as for prevention of personal respon-
sibility, and, at the bottom line, for successful finalization of
planned researches – without these there is no progress in
medicine and no survival of the humankind.
Secondly, it is necessary to have clearly and completely
defined terms within the national legislation in order to make
researchers aware what are the conditions; those also have to
be formulated in cooperation with experts from areas of
medicine, ethics and law, taking into the account standards
set in international regulations in this field.
Thirdly, researchers shall fulfil terms for getting valid
consent in the easiest way if these terms are stipulated within
one legal document.
Having all in mind, we could note that at least one of the
indicated prerequisites was surely fulfilled in Serbia: obviously
cooperation with physicians, ethicists and lawyers existed
when terms for subject’s valid consent were defined; require-
ments contained in international legal and ethic documents
were also taken into account. This is proved by the fact that
Serbian medical law today requires fulfilment of wide span ofStrana 594 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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terms for duly valid consent of the subject when participating
clinical research, and content of some of those terms is well-
defined both quantitatively and qualitatively (ex. number and
sort of information with which subject in Serbia has to be in-
formed). Serbian regulations, however, have two shortcom-
ings, resulting primarily from the omission of lawyers.
First, some of the terms are not fully defined and some
have no sufficiently precise definition – this is underlined by
the paper and its authors gave also concrete suggestions to
amend and make subject regulations more precise (ex. sug-
gestions regarding relation of legal competency, legal age
and subjects reasoning capability; regarding the need to get
consent of guardianship authorities in certain situations; re-
garding actions of persons unable to give consent and having
no legal representative, etc.).
The second weakness of Serbian regulations related to
clinical researches stems from the first one: in order to re-
move its incompleteness and impreciseness, it is necessary to
consult numerous legal texts – this exceeds capacities of any
physician–researcher. Therefore, we consider important
changes and amendments of the basic law in this field – the
Medicines and Medical Devices Act in ways suggested in the
paper, in order to gather all rules in Serbia regarding the pro-
vision of the subject’s consent in one place and by this en-
able undisturbed performance of researchers.
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